Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Go back to Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 28.75 +0.14 (0.49%)
Previous Close $28.61    52 Week High $5.17 
Open $28.50    52 Week Low $0.94 
Day High $29.28    P/E N/A 
Day Low $28.49    EPS $0.00 
Volume 1,175,804